LabStyle Innovations' Dario Diabetes Management Solution Launches in Canada
Available now at www.mydario.ca and coming soon to select pharmacies
Jun 25, 2015
CAESAREA, Israel, June 25, 2015 /PRNewswire/ -- On the heels of receiving regulatory approval in Canada for the Dario™ Diabetes Management Solution, LabStyle Innovations Corp. (DRIO), today announced the Dario is now available for sale in Canada. The compact all-in-one system that helps people with diabetes monitor blood sugar levels and proactively manage their disease using their smartphone or tablet, is distributed by Auto Control Medical. Now available through www.mydario.ca, Dario's suggested retail price is $39.95 and it will be available at selected pharmacies including London Drugs.
Dario connects via a headphone jack to turn a mobile device into a glucose monitor, and comes equipped with a lancing device and test strips to take blood samples on the spot. It provides the diabetes patient's real-time and historical blood glucose data to spot patterns, recommend treatments and support behavior changes. Its web interface also makes it easy to get upgrades and share health information with healthcare providers and loved ones.
"With Dario, diabetes management is not only about generating accurate blood glucose measurements, but about self-management and providing practical information, analysis and suggestions to help those with diabetes make better-informed decisions and improve their lifestyle," stated Erez Raphael, President and CEO of LabStyle Innovations.
"We believe patients and healthcare providers will benefit from Dario's unique features," commented Robert Burgy, president of Auto Control Medical, the exclusive distributor of Dario in Canada. "With the ability to track their food intake and insulin use, people will have a better understanding of how to optimally manage their diabetes, all through the smartphone they've always got with them."
As an all-in-one system, Dario combines a lancing device to obtain a blood sample, a proprietary disposable test strip cartridge with 25 strips, and a glucose meter that's driven via the user's mobile device. Unlike conventional glucose monitors, there is no carrying case or batteries to replace, and the system works on both Apple and Android devices.
About Auto Control Medical
Auto Control Medical is a privately owned Canadian company with a focus on self-monitoring products. Headquartered in Mississauga Ont., it distributes health monitoring products through pharmacies and homecare stores coast to coast.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB: DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ Diabetes Management Solution. Dario™ empowers people with diabetes to take charge of their health with the right tools, insights, and support in their pocket. With access to both real-time and historical blood glucose data, Dario™ is designed to spot patterns, recommend the right treatments and support behavior change efforts.
Dario™ is a platform that combines an all-in-one, blood glucose meter, smart phone application (iOS & Android), website application and treatment tools to support more proactive and better informed decisions by patients, doctors and healthcare systems. The stylish and compact self-monitoring system combines a lancet to obtain a blood sample, a proprietary disposable test strip cartridge and a smartphone-driven glucose meter. LabStyle Innovations is led by an experienced management team with vast software, medical device and technology experience and is guided by a world class board of directors and scientific advisory board. For more information: www.myDario.com and http://myDario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Press and Investor Relations
1 800 896 9062
SOURCE LabStyle Innovations Corp.